AstraZeneca follows rival Boehringer in capping out-of-pocket costs for inhalers

 Drugmaker AstraZeneca (AZN.L) said on Monday it would cap out-of-pocket costs for its inhaled respiratory products at $35 per month in the United States, following a similar move by rival Boehringer Ingelheim earlier in the month.